49 / 182
CARBON FOOTPRINT
The carbon footprint results for South Africa determined by ‘Carbon
Calculated’ are as follows:
2016
2015
Tonnes
Tonnes
Scope 1
Equipment owned or controlled
12 045
12 442
Air conditioning and refrigeration gas
refills
247
125
Vehicle fleet
2 220
2 404
Scope 2
Electricity
47 612
51 687
Total Scope 1 and 2
62 124
66 658
Scope 3
Business travel
1 729
1 272
Employee commute
4 070
3 918
Transportation & distribution of raw
materials and sold goods
17 751
16 893
Packaging materials
15 400
20 328
Consumption of office paper
44
68
Total waste (landfill, recycled & effluent)
3 902
3 337
Water & wastewater
525
581
Total Scope 3
43 421
46 397
Total Scope 1, 2 and 3
105 545
113 055
Non-Kyotogas
2 129
2 424
Grand total
107 674
115 479
DRUG MANAGEMENT AND
DEVELOPMENT
Being a healthcare company, manufacturing medicines, the safety
of quality and efficacious products supplied to our patients are of
paramount importance. This is managed by the Drug Management
and Development Team. This team comprises Research and
Development, Quality Assurance, Medical Affairs and Compliance.
Research and Development
Adcock Ingram does not undertake or support any animal studies
or test any of our products on animals. The Group uses accredited
agents to carry out any bioequivalence studies required, usually
known as Clinical Research Organisations (CRO’s). The policies
which these appointed CRO’s have in place to govern their studies
are aligned to local and international clinical research guidelines,
such as those of the local Medicines Control Council (MCC) and
the International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH-guidelines).
Quality Assurance
Quality Assurance (QA) applies quality tools to monitor and control
processes to assist in continuous improvement of our products. QA
mitigates product quality risks through evaluations of customer
complaints, product manufacturing changes and supplier changes.
Medical Affairs
Our pharmacovigilance system matches international standards to
ensure the safety of our medicines and that of the patients who use
them.
Pharmacovigilance, the ongoing surveillance of medicines safety
data and the appropriate response thereto, is a requirement for any
pharmaceutical company. Guided by the regulations of the MCC,
Adcock Ingram has a robust system in place to detect, assess and
manage adverse drug reactions to the medicines we market.
The MCC requires each company to have appropriate
pharmacovigilance systems in place that will provide for the proper
management of safety data for its medicines and to ensure that
appropriate action can be taken when necessary.
Reports of adverse reactions, however minor they might seem, are
actively collected from various stakeholders including customers
and healthcare professionals. The Group’s systems are set up for ease
of collection of relevant reports, recording and evaluation thereof
and the reporting to the MCC, as required.
Compliance
The Compliance Department ensures that all promotional material
and product packaging is legally compliant with the relevant
statutory laws, regulations, rules and standards.
WHISTLE-BLOWING FACILITY
In pursuit of maintaining a commercially sustainable and ethical
environment, free of criminal behavior, Adcock Ingram has a
whistle-blowing facility to encourage employees and other
stakeholders to report any suspected misdemeanor, anonymously.
Inappropriate, unethical or illegal activity can be reported through
the independently operated service, 24 hours per day and 365 days
per year. The service is promoted extensively through internal
communication tools.
Increased efforts during the year to promote the availability of the
whistle-blowing facility resulted in a significant increase in the
amount of
reports.
All complaints lodged through this service are investigated,
appropriate disciplinary action instituted if necessary and then
reported to the Board through the Social, Ethics and Transformation
Committee. During the year 40 reports were lodged of which
75% related to human capital issues and the balance to dishonest
conduct. After investigation, 65% of the reports were dismissed as
unfounded.
FIVE
SIX
THREE
ONE
FOUR
TWO
OUR PERFORMANCE
(continued)
| 45
Integrated Report 2016